TWi Biotechnology

Developing potentially first-in-class therapies for Epidermolysis Bullosa, Simplex(EBS) and CNS disorders via 505(b)(2) pathway.

[TWi Biotechnology @TWiBiotech]

TWi Biotechnology today announced the completion of patient enrollment in its global Phase 2/3 EBShield study of AC-203 for epidermolysis bullosa simplex (EBS). A total of 81 patients have been enrolled across 37 clinical sites in 19 countries, reflecting the global scope of this randomized, double-blind, vehicle-controlled study.

With enrollment now completed, the study will continue to progress toward data analysis and the anticipated top-line efficacy readout by the end of 2026. Upon successful results, the company plans to initiate pre-NDA discussions with regulatory authorities to support future registration.

For more details on the completion of enrollment in the global Phase 2/3 EBShield study of AC-203 for EBS, please visit our official announcement at https://t.co/4tkoEt00GB

[TWi Biotechnology @TWiBiotech]

@EBResearch @Padres @Mariners EB research is something everyone can rally behind. 🦋⚾
But with all due respect to bipartisan cooperation… Go Padres. 💙🤎

[TWi Biotechnology @TWiBiotech]

@RareRevolutionM @InterDEBRA Because quality of life includes love life too. 💙🦋 Sending love from Taiwan! 🇹🇼

[Good Morning Britain @GMB]

Every day is an uphill battle for 13-year-old Jasmine Ritchie, who has a rare skin condition called Epidermolysis Bullosa, also known as butterfly skin, which causes her skin to blister and tear at the slightest touch.

Jasmine's mum, Anna, and Grandad Robert took on their own challenge to raise money for those living with the skin disorder by climbing Mount Kilimanjaro.

Anna recalls the experience as Graeme Souness explains why raising awareness and money is so important.

@susannareid100 | @edballs | @CharityDEBRA

[TWi Biotechnology @TWiBiotech]

@CharityDEBRA We are so excited to finally see progress in EBS research. Every new study brings renewed hope to patients and families living with this devastating disease. Sending love from Taiwan and cheering for continued innovation in the EB community. 💙🧡

[TWi Biotechnology @TWiBiotech]

@debraOfAmerica Can’t wait to meet all of y’all in LA this summer! Sending love from Taiwan. 💙🧡

[TWi Biotechnology @TWiBiotech]

We are excited to officially join X and look forward to engaging with the global biotech and EB communities!

#RareDisease #Dermatology #505b2 #EBS #Epidermolysisbullosa